Bone Biologics Corp (BBLG) — Cash Flow-to-Debt Ratio
Bone Biologics Corp (BBLG) has a Cash Flow-to-Debt Ratio of -1.71x as of December 2025, meaning its operating cash flow of $-714.76K could theoretically repay -2% of its total liabilities ($418.59K) in one year. See working capital position of Bone Biologics Corp to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Bone Biologics Corp Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Bone Biologics Corp across 14 annual periods. Also explore Bone Biologics Corp (BBLG) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Bone Biologics Corp (2012–2025)
Year-by-year debt coverage analysis for Bone Biologics Corp. For market capitalisation and broader financial context, see BBLG market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.43x | $-2.69 Million | $418.59K | ▲ +41.1% |
| 2024 | -10.92x | $-4.12 Million | $377.71K | ▲ +5.0% |
| 2023 | -11.49x | $-9.56 Million | $831.40K | ▼ -721.0% |
| 2022 | -1.40x | $-3.57 Million | $2.55 Million | ▲ +88.6% |
| 2021 | -12.30x | $-1.23 Million | $99.91K | ▼ -39338.3% |
| 2020 | -0.03x | $-426.93K | $13.69 Million | ▲ +88.6% |
| 2019 | -0.27x | $-3.25 Million | $11.90 Million | ▲ +35.8% |
| 2018 | -0.43x | $-4.10 Million | $9.64 Million | ▼ -17.5% |
| 2017 | -0.36x | $-3.33 Million | $9.19 Million | ▲ +52.5% |
| 2016 | -0.76x | $-7.33 Million | $9.61 Million | ▼ -67.0% |
| 2015 | -0.46x | $-3.55 Million | $7.76 Million | ▼ -24.7% |
| 2014 | -0.37x | $-2.76 Million | $7.52 Million | ▼ -34024.3% |
| 2013 | 0.00x | $-6.12K | $5.70 Million | ▲ +98.9% |
| 2012 | -0.10x | $-447.00 | $4.68K | — |